Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ankai Xu has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Wei Wang

    Department of Orthopedics, The Quzhou Affiliated Hospital, Wenzhou Medical University, Quzhou People’s Hospital

    3 shared publications
  • Bing Liu

    Department of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine

    2 shared publications
  • Chen Chen

    Department of Orthopedics, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital

    2 shared publications
  • Huimin Tao

    Department of Orthopedics Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88, Jiefang Road, Hangzhou 310009, China

    2 shared publications
  • Jinku Guo

    Department of Orthopedics, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital

    2 shared publications
  • Jun Xie

    Department of Orthopedics, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital

    2 shared publications

Latest Publications

  • Open Access

    Integrative functional-genomics analysis identifies CCT3 as a prognostic biomarker in osteosarcoma, involving the beta-catenin/c-MYC axis in malignant progression

    by Jiangbao Xu, Shengkun Hong, Zhuo Zhang, Wei Wang, Ankai Xu

    Objective: Osteosarcoma prognosis remains challenging, and reliable molecular determinants are lacking. We integrated multi-dimensional functional genomic and transcriptomic data to construct a prognostic model and investigated the key candidate gene CCT3 in osteosarcoma malignancy. Methods: We intersected CRISPR-Cas9 dependency genes with differentially expressed genes to derive a 64-gene candidate pool, followed by stepwise Cox regression to build a risk model. Model performance was validated in training and external cohorts. Immune microenvironment, drug sensitivity, and experimental validation were performed following CCT3 knockdown. Results: An 8-gene risk model was constructed and significantly stratified overall survival. The high-risk group showed lower immune scores, reduced immune-cell infiltration, and downregulation of multiple immune checkpoint genes, indicating an immune-poor phenotype. Among 7 drugs with differential sensitivity, the high-risk group was more sensitive to 6 agents, including AZ6102, while showing resistance to Entospletinib. CCT3 was overexpressed in osteosarcoma tissues and cell lines; its knockdown suppressed proliferation and clonogenicity. Mechanistically, CCT3 depletion attenuated Wnt/beta-catenin signaling and reduced stemness markers CD24 and c-MYC. Conclusion: Our integrative approach establishes an effective prognostic model for osteosarcoma and identifies CCT3 as a pro-tumorigenic gene, likely through the beta-catenin/c-MYC axis, representing a promising prognostic biomarker and therapeutic vulnerability.

  • Open Access

    SULT1A1 at a differentiation branch point regulates osteosarcoma cell proliferation and melatonin-mediated anti-tumor activity

    by Jun Xie, Chao Qian, Jinku Guo, Wei Wang, Chen Chen, Renjie Peng, Ankai Xu

    Background: Circadian disruption is increasingly recognized as a contributing factor in tumorigenesis and tumor evolution; however, the role of circadian genes in osteosarcoma cell fate determination and therapeutic response remains to be fully elucidated. Methods: Gene expression data from GEO were integrated to construct a prognostic model of circadian rhythm-annotated genes based on melatonin-related signatures, validated using the TARGET database. Single-cell RNA-seq and pseudotime trajectory inference were performed to characterize osteosarcoma cell states and identify branch-point genes. We queried publicly available CRISPR-Cas9 dependency data (DepMap) and performed functional assays in osteosarcoma cell lines. Results: A five-gene circadian rhythm-annotated prognostic signature was established and validated. The intersection of the signature with branch-point genes and circadian rhythm-annotated genes identified SULT1A1 . CRISPR-Cas9 screening data confirmed that SULT1A1 is essential for osteosarcoma cell proliferation across multiple cell lines. Experimentally, SULT1A1 knockdown significantly suppressed cell proliferation and colony formation, and markedly enhanced the anti-tumor efficacy of melatonin in osteosarcoma cells. Conclusions: Our findings identify SULT1A1 as a candidate circadian-associated gene localized at an osteosarcoma differentiation branch point, where it may participate in modulating cell proliferation and sensitivity to melatonin. This study uncovers a candidate mechanism potentially linking circadian gene networks to tumor cell state plasticity, with potential implications for understanding non-genetic tumor adaptation and developing chronotherapeutic strategies in osteosarcoma.

  • Open Access

    Cyclovirobuxine D suppresses cancer stemness in osteosarcoma with implication of the noncanonical NF-kappaB pathway

    by Jinku Guo, Yingfeng Cao, Kaipen Jin, Bing Liu, Wei Wang, Chen Chen, Jun Xie, Ankai Xu

    Background: Cyclovirobuxine D (CVB-D), an alkaloid from Buxus microphylla, exhibits anticancer effects in various tumors, but its role in osteosarcoma remains unexplored. This study investigates its efficacy and mechanism in osteosarcoma. Methods: We screened a drug library and evaluated CVB-D’s effects on osteosarcoma cell lines using CCK-8 and colony formation assays. Saos2 and K7M2 cells were selected for further analysis. Flow cytometry assessed apoptosis and cell cycle. RNA-seq identified downstream pathways, including NF-kappaB, and stemness markers (CD24, ALDH1A1). Stemness was examined via serum-free suspension culture, and NF-kappaB pathway activator Diprovocim was used in rescue experiments. A xenograft mouse model validated the findings. Results: CVB-D suppressed proliferation, stemness, and induced apoptosis in osteosarcoma. These effects may be partially mediated through the p-NF-kappaB2/NF-kappaB2 axis and were reversible upon NF-kappaB pathway activation. Conclusion: CVB-D inhibits osteosarcoma possibly via the non-canonical NF-kappaB pathway, suggesting a potential therapeutic strategy.


  • Open Access

    Cell Differentiation Trajectory-Associated Molecular Classification of Osteosarcoma

    by Ankai Xu, Chao Qian, Jinti Lin, Wei Yu, Jiakang Jin, Bing Liu, Huimin Tao

    This study aims to investigate the differentiation trajectory of osteosarcoma cells and to construct molecular subtypes with their respective characteristics and generate a multi-gene signature for predicting prognosis. Integrated single-cell RNA-sequencing (scRNA-seq) data, bulk RNA-seq data and microarray data from osteosarcoma samples were used for analysis. Via scRNA-seq data, time-related as well as differentiation-related genes were recognized as osteosarcoma tumor stem cell-related genes (OSCGs). In Gene Expression Omnibus (GEO) cohort, osteosarcoma patients were classified into two subtypes based on prognostic OSCGs and it was found that molecular typing successfully predicted overall survival, tumor microenvironment and immune infiltration status. Further, available drugs for influencing osteosarcoma via prognostic OSCGs were revealed. A 3-OSCG-based prognostic risk score signature was generated and by combining other clinic-pathological independent prognostic factor, stage at diagnosis, a nomogram was established to predict individual survival probability. In external independent TARGET cohort, the molecular types, the 3-gene signature as well as nomogram were validated. In conclusion, osteosarcoma cell differentiation occupies a crucial position in many facets, such as tumor prognosis and microenvironment, suggesting promising therapeutic targets for this disease.


  • Open Access

    Identification of a Programmed Cell Death-related Signature for Prediction of Osteosarcoma

    by Ankai Xu, Jinti Lin, Wei Yu, Jiakang Jin, Bing Liu, Huimin Tao

    Background: This study aims to perform bioinformatics analysis of programmed cell death-related genes (PCDGs) in osteosarcoma, and to construct a multi-gene signature for predicting the prognosis.Methods: The functional enrichment analysis was applied for prognostic PCDGs, and PPI network as well as drug-gene interactions were constructed. In order to set up the prognosis evaluation system, we established a prognosis model by integrating PCDGs. The Least Absolute Shrinkage and Selection Operator (LASSO) logistic regression analysis as well as the multivariate Cox proportional hazard regression analysis were used to construct the five-genes signature (MUC1, TCF7L2, TGFB2, TRIAP1, CBS) for prediction in Gene Expression Omnibus (GEO) cohort. According to the median risk score, survival analysis was conducted to evaluate the prognostic value of the risk score in GEO cohort. Next, by combining other clinic-pathological independent prognostic factor, stage at diagnosis, a nomogram was established to predict individual survival probability. Result: GO analysis showed that the 15 prognostic PCDGs were mainly enriched in apoptotic signaling pathway, regulation of secretion and p53 signaling pathway. KEGG analysis showed that aforesaid genes were mainly related to PI3K-Akt signaling pathway, diverse neoplasms signaling pathway and hepatitis B. Drug-gene interactions displayed available drugs for influencing osteosarcoma via programmed cell death, such as adalimumab, tacrolimus and sirolimus. The risk score was constructed based on 5 genes and patients were significantly divided into high-risk and low-risk groups according to overall survival. In multivariate Cox regression analysis, risk score was still an independent prognostic factor (HR = 2.526, 95% CI = 1.597−3.994, P < 0.001). Cumulative curve showed that low-risk score patients were significantly had better prognosis than that of patients with high-risk score (P < 0.001). The external independent TARGET cohort proved the validity of risk score model and the nomograph.Conclusion: From the facet of programmed cell death, we provided a multi-gene signatureand the nomograph for the prognostic predictors of osteosarcoma patients, and available drugs displayed may provide promising treatment strategies.

  • Comprehensive therapeutics targeting the corticospinal tract following spinal cord injury

    by An-Kai Xu, Zhe Gong, Yu-Zhe He, Kai-Shun Xia, Hui-Min Tao

    Spinal cord injury (SCI), which is much in the public eye, is still a refractory disease compromising the well-being of both patients and society. In spite of there being many methods dealing with the lesion, there is still a deficiency in comprehensive strategies covering all facets of this damage. Further, we should also mention the structure called the corticospinal tract (CST) which plays a crucial role in the motor responses of organisms, and it will be the focal point of our attention. In this review, we discuss a variety of strategies targeting different dimensions following SCI and some treatments that are especially efficacious to the CST are emphasized. Over recent decades, researchers have developed many effective tactics involving five approaches: (1) tackle more extensive regions; (2) provide a regenerative microenvironment; (3) provide a glial microenvironment; (4) transplantation; and (5) other auxiliary methods, for instance, rehabilitation training and electrical stimulation. We review the basic knowledge on this disease and correlative treatments. In addition, some well-formulated perspectives and hypotheses have been delineated. We emphasize that such a multifaceted problem needs combinatorial approaches, and we analyze some discrepancies in past studies. Finally, for the future, we present numerous brand-new latent tactics which have great promise for curbing SCI.